No Data
No Data
Skye Bioscience Added to Russell 2000 and Russell 3000 Indexes
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and
Private Equity Firms Invested in Skye Bioscience, Inc. (NASDAQ:SKYE) Copped the Brunt of Last Week's US$76m Market Cap Decline
Key Insights The considerable ownership by private equity firms in Skye Bioscience indicates that they collectively have a greater say in management and business strategy The top 4 shareholders own
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $21
Oppenheimer analyst Jay Olson maintains $SKYE BIOSCIENCE INC(SKYE.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 42.9% and
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Skye Bioscience (NASDAQ:SKYE) with a Overweight and maintains $14 price target.
No Data
Skinny bulldogOP : Look at the other company in the same industry you will know. The problem is, how high it can go.